Sol-Gel Technologies (SLGL) Assets Average (2017 - 2026)
Sol-Gel Technologies (SLGL) reported Assets Average of $44.2 million for Q1 2026, up 40.63% year-over-year from $31.5 million in Q1 2025, and up 37.14% quarter-over-quarter from $32.3 million in Q4 2025.
Sol-Gel Technologies (SLGL) Assets Average (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 10 years of Assets Average data on file, last reported at $44.2 million in Q1 2026.
- Assets Average for Q1 2026 came in at $44.2 million, up 40.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.2 million (up 40.63% YoY), and the FY2025 annual result was $32.9 million, down 18.94% from the prior year.
- Assets Average advanced to $44.2 million in Q1 2026 per SLGL's latest filing, from $32.3 million in the prior quarter.
- Over five years, Assets Average peaked at $62.6 million in Q1 2022 and troughed at $31.5 million in Q1 2025.
- A 5-year average of $44.9 million and a median of $44.2 million in 2026 frame the typical range for Assets Average.
- The sharpest annual moves came in 2025 and 2026: Assets Average dropped 26.16% in 2025, then surged 40.63% in 2026.
- A 5-year view of Assets Average shows it stood at $49.0 million in 2022, then fell by 2.83% to $47.6 million in 2023, then decreased by 17.16% to $39.4 million in 2024, then declined by 18.16% to $32.3 million in 2025, then soared by 37.14% to $44.2 million in 2026.
- Business Quant data shows SLGL's Assets Average at $44.2 million in Q1 2026, $32.3 million in Q4 2025, and $36.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 26.03 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 40.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 660.38 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 44.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.23 Mn |
| Dec 31, 2025 | 32.25 Mn |
| Sep 30, 2025 | 36.95 Mn |
| Jun 30, 2025 | 33.19 Mn |
| Mar 31, 2025 | 31.45 Mn |
| Dec 31, 2024 | 39.41 Mn |
| Sep 30, 2024 | 42.49 Mn |
| Jun 30, 2024 | 40.96 Mn |
| Mar 31, 2024 | 42.60 Mn |
| Dec 31, 2023 | 47.57 Mn |
| Sep 30, 2023 | 52.48 Mn |
| Jun 30, 2023 | 52.07 Mn |
| Mar 31, 2023 | 47.84 Mn |
| Dec 31, 2022 | 48.96 Mn |
| Sep 30, 2022 | 53.14 Mn |
| Jun 30, 2022 | 55.52 Mn |
| Mar 31, 2022 | 62.62 Mn |
| Dec 31, 2021 | 61.01 Mn |
| Sep 30, 2021 | 49.62 Mn |
| Jun 30, 2021 | 50.01 Mn |